Takeda Pharmaceutical Co. Ltd.'s Livtencity (maribavir) will be available in the coming days for patients with a common and serious post-transplant infection, cytomegalovirus, that is refractory to treatment.
Cleared by the US Food and Drug Administration on 23 November, the antiviral is approved for adults and pediatric patients...







